CAR-T Immunotherapy Clears Psoriasis: A 92.6% PASI Drop
Anti-CD19 CAR-T therapy given for lymphoma produced a 92.6% PASI reduction in a 45-year plaque psoriasis case, fueling review of CAR strategies for immune reset.
Topic
Topic
Anti-CD19 CAR-T therapy given for lymphoma produced a 92.6% PASI reduction in a 45-year plaque psoriasis case, fueling review of CAR strategies for immune reset.
JAAD published an expert opinion on October 8, 2026 comparing efficacy and tolerability of hedgehog pathway inhibitors for locall…
The Institute of Cancer Research has treated the first patient in a new clinical trial targeting immunotherapy resistance in lung…
First patients enrolled in NCT07504796: Signatera-positive melanoma patients randomized at week six to ipilimumab escalation or c…
A clinical trial reports that combining an IDO1 inhibitor with a melanoma vaccine did not increase tumor-fighting T cells, underm…
Avelumab demonstrates effectiveness against Merkel cell carcinoma in a real-world population, Medscape reports, extending evidenc…
A major review reported by Bioengineer.org maps effective post-treatment interventions for melanoma survivors and identifies an u…
A personalised mRNA cancer vaccine stopped melanoma from returning, Gavi reports, marking a milestone for individualised neoantig…
New Dermatology Times guidance examines how to order hedgehog inhibitors with surgery, radiation and immunotherapy in advanced ba…
Northwestern University researchers report that radiotherapy reprograms the immune response in a rare cutaneous malignancy. The i…